We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pacific Biosciences of California (PACB) Stock Drops Despite Market Gains: Important Facts to Note
Read MoreHide Full Article
Pacific Biosciences of California (PACB - Free Report) ended the recent trading session at $1.66, demonstrating a -1.19% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily gain of 0.72%. Meanwhile, the Dow experienced a rise of 0.3%, and the technology-dominated Nasdaq saw an increase of 1.12%.
Shares of the maker of genetic analysis technology have appreciated by 15.86% over the course of the past month, outperforming the Medical sector's gain of 12.48%, and the S&P 500's loss of 0.9%.
The upcoming earnings release of Pacific Biosciences of California will be of great interest to investors. It is anticipated that the company will report an EPS of -$0.14, marking a 7.69% fall compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $42.1 million, indicating a 5.86% increase compared to the same quarter of the previous year.
PACB's full-year Zacks Consensus Estimates are calling for earnings of -$0.41 per share and revenue of $165.8 million. These results would represent year-over-year changes of +22.64% and +3.62%, respectively.
Any recent changes to analyst estimates for Pacific Biosciences of California should also be noted by investors. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Pacific Biosciences of California is holding a Zacks Rank of #2 (Buy) right now.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 159, which puts it in the bottom 36% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Pacific Biosciences of California (PACB) Stock Drops Despite Market Gains: Important Facts to Note
Pacific Biosciences of California (PACB - Free Report) ended the recent trading session at $1.66, demonstrating a -1.19% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily gain of 0.72%. Meanwhile, the Dow experienced a rise of 0.3%, and the technology-dominated Nasdaq saw an increase of 1.12%.
Shares of the maker of genetic analysis technology have appreciated by 15.86% over the course of the past month, outperforming the Medical sector's gain of 12.48%, and the S&P 500's loss of 0.9%.
The upcoming earnings release of Pacific Biosciences of California will be of great interest to investors. It is anticipated that the company will report an EPS of -$0.14, marking a 7.69% fall compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $42.1 million, indicating a 5.86% increase compared to the same quarter of the previous year.
PACB's full-year Zacks Consensus Estimates are calling for earnings of -$0.41 per share and revenue of $165.8 million. These results would represent year-over-year changes of +22.64% and +3.62%, respectively.
Any recent changes to analyst estimates for Pacific Biosciences of California should also be noted by investors. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Pacific Biosciences of California is holding a Zacks Rank of #2 (Buy) right now.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 159, which puts it in the bottom 36% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.